Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know

Zoetis shares have plunged (24.8% YTD, ~29.9% over the past year) after FDA post‑approval safety scrutiny of its OA monoclonal antibody therapies Librela (dogs) and Solensia (cats) and a May 2025 government analysis showing ~9x higher musculoskeletal adverse-event reporting versus six comparator OA drugs; an independent panel flagged a suspected causal link to accelerated joint destruction. Librela and Solensia posted year‑over‑year sales declines in Q2 and Q3 2025, prompting Zoetis to lower 2025 revenue guidance to $9.40–$9.475 billion (from $9.45–$9.6B) while maintaining adjusted EPS guidance of $6.30–$6.40. Management is leaning on strong parasiticide, dermatology and diagnostics momentum and new long‑acting EU approvals (Lenivia, Portela) to try to restore growth in 2026.

Analysis

Market structure: Zoetis’ Librela/Solensia safety saga creates a clear winner/loser split — short-term winners are competing parasiticides and dermatology franchises (Simparica, Revolution, Apoquel, Cytopoint) that can capture share; losers are ZTS’s OA monoclonals and any vendors tightly bundled with those SKUs. Expect pricing power erosion for Librela/Solensia (volume down mid-to-high single digits in Q2–Q3 2025) and faster uptake of 3-month NGF options in EU (Lenivia/Portela) as vets shift to perceived safer/less-frequent dosing. Net supply-demand: demand shock for monthly OA injections, partial offset by demand growth in parasiticides; inventory risk for ZTS if prescriptions rebooking lags.

Risk assessment: Tail risks include an FDA escalation or label withdrawal (10–25% probability in 12 months) triggering a 30–50% earnings hit and litigation; operational risk includes vet channel reputational contagion depressing uptake across companion-animal portfolio. Time horizons: immediate (days) — elevated IV and potential short squeezes around news; short-term (weeks–months) — monitoring FDA, independent panel releases, and q4 sales cadence; long-term (2026+) — recovery contingent on uptake of Lenivia/Portela and sustained parasiticide growth. Hidden dependency: vet recommendations drive >60% of prescriptions; adverse-event media cycles can non-linearly reduce new starts.

Trade implications: Tactical ideas — establish a 2–3% long ZTS (ticker ZTS) position targeting a reversion to pre-crisis multiples by end-2026 if no FDA escalation, but hedge with a 6–9 month 20/30% OTM put spread sized at 30–50% notional. Pair trade: long CRMD (1–2% weighting) vs short ZTS (1% weighting) to capture analyst momentum in small-cap biotech while shorting a large-cap reputational recovery lag; trim exposure if CRMD volatility spikes >40%. Options: consider a calendar call spread on ZTS (buy 12m, sell 3m) to monetize elevated near-term IV while keeping long-dated upside optionality.

Contrarian angles: Consensus underprices the resilience of Zoetis’ non-OA franchises — if parasiticides + dermatology sustain 12–15% combined growth in 2026, ZTS upside materializes even with prolonged OA weakness. Reaction may be overdone if independent analyses are confounded by reporting bias; a binary FDA adverse-action outcome is unlikely in <90 days. Historical parallels: post-launch safety scares (e.g., human mAbs) often cause 30–40% troughs followed by multi-quarter recoveries once label updates and targeted surveillance reduce uncertainty. Key unintended consequence: aggressive shorting could amplify management’s drive to accelerate M&A for diversification — watch for M&A rumors as a 6–12 month bullish catalyst.

Key Decisions for Investors

• Establish a 2–3% long position in ZTS (Zoetis) at current levels as a recovery play into 2026, but size with conviction only if maintaining EPS guidance of $6.30–$6.40 and revenue stays within revised $9.4–$9.475bn; hedge with a 6–9 month 20/30% OTM put spread sized at 30–50% of the long notional to cap downside.
• Initiate a pair trade: long CRMD (1–2% portfolio weight) vs short ZTS (1% weight) to exploit positive estimate revisions in CorMedix and negative sentiment in Zoetis; exit or rebalance if CRMD IV >40% or ZTS moves >20% intraday on regulatory news.
• Sell a 3-month covered call (write) against new or existing ZTS longs if near-term implied volatility rises >25% above historical — collect premium while keeping long-dated upside exposure via buying 9–12 month calls (calendar spread).
• Reduce cyclically exposed pet healthcare beta by 3–5%: increase allocations to defensive human healthcare/large-cap biopharma or to pet parasiticide leaders (if available as pure-plays) until FDA clarity (monitor next 30–90 days for agency communications or independent panel publications).
• Set hard risk triggers: trim/exit ZTS longs if (a) FDA issues a safety communication that escalates to label restriction or withdrawal, or (b) Librela/Solensia revenue decline exceeds 15% QoQ; conversely add to ZTS if quarterly parasiticide/derm revenue growth >10% and no new safety actions within 90 days.